Recombinant Anti-c-Rel antibody [EPR2559(2)] (ab133251)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR2559(2)] to c-Rel
- Suitable for: WB, IP
- Knockout validated
- Reacts with: Human
Related conjugates and formulations
Overview
-
Product name
Anti-c-Rel antibody [EPR2559(2)]
See all c-Rel primary antibodies -
Description
Rabbit monoclonal [EPR2559(2)] to c-Rel -
Host species
Rabbit -
Tested applications
Suitable for: WB, IPmore details -
Species reactivity
Reacts with: Human -
Immunogen
Synthetic peptide. This information is proprietary to Abcam and/or its suppliers.
-
Positive control
- WB: HAP1, HuT-78, and HeLa cell lysates. IP: HeLa cell lysate.
-
General notes
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle. -
Storage buffer
pH: 7.20
Preservative: 0.01% Sodium azide
Constituents: 0.05% BSA, 40% Glycerol (glycerin, glycerine), 59% PBS -
Concentration information loading...
-
Purity
Protein A purified -
Clonality
Monoclonal -
Clone number
EPR2559(2) -
Isotype
IgG -
Research areas
Associated products
-
Alternative Versions
-
Isotype control
-
Positive Controls
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab133251 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
WB | (1) |
1/1000. Predicted molecular weight: 68 kDa.
For unpurified use at 1/10000 - 1/50000. |
IP |
1/10 - 1/100.
|
Notes |
---|
WB
1/1000. Predicted molecular weight: 68 kDa. For unpurified use at 1/10000 - 1/50000. |
IP
1/10 - 1/100. |
Target
-
Function
Proto-oncogene that may play a role in differentiation and lymphopoiesis. NF-kappa-B is a pleiotropic transcription factor which is present in almost all cell types and is involved in many biological processed such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. The NF-kappa-B heterodimer RELA/p65-c-Rel is a transcriptional activator. -
Sequence similarities
Contains 1 RHD (Rel-like) domain. -
Cellular localization
Nucleus. - Information by UniProt
-
Database links
- Entrez Gene: 5966 Human
- Omim: 164910 Human
- SwissProt: Q04864 Human
- Unigene: 631886 Human
-
Alternative names
- Avian reticuloendotheliosis antibody
- C REL antibody
- C Rel protein antibody
see all
Images
-
Purified ab133251 at 1/20 dilution (0.6µg) immunoprecipitating c-Rel in HeLa whole cell lysate.
Lane 1 (input): HeLa (Human cervix adenocarcinoma epithelial cell) whole cell lysate 10µg
Lane 2 (+): ab133251 + HeLa whole cell lysate.
Lane 3 (-): Rabbit monoclonal IgG (ab172730) instead of ab133251 in HeLa whole cell lysate.
VeriBlot for IP Detection Reagent (HRP) (ab131366) (1/5000 dilution) was used for Western blotting.
Blocking Buffer and concentration: 5% NFDM/TBST.
Diluting buffer and concentration: 5% NFDM/TBST.
Observed band size: 78 kDa
Fresh lysate is required to avoid protein degradation. -
All lanes : Anti-c-Rel antibody [EPR2559(2)] (ab133251) at 1/1000 dilution (Purified)
Lane 1 : HeLa (Human cervix adenocarcinoma epithelial cell) whole cell lysate
Lane 2 : HuT-78 (Human Sezary syndrome cutaneous T lymphocyte) whole cell lysate at 20 µg
Secondary
All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/20000 dilution
Predicted band size: 68 kDa -
Lane 1: Wild-type HAP1 cell lysate (20 µg)
Lane 2: c-Rel knockout HAP1 cell lysate (20 µg)
Lane 3: HeLa cell lysate (20 µg)
Lanes 1 - 3: Merged signal (red and green). Green - ab133251 observed at 75 kDa. Red - loading control, ab8245, observed at 37 kDa.
ab133251 was shown to recognize c-Rel when c-Rel knockout samples were used, along with additional cross-reactive bands. Wild-type and c-Rel knockout samples were subjected to SDS-PAGE. ab133251 and ab8245 (loading control to GAPDH) were diluted 1/1000 and 1/2000 respectively and incubated overnight at 4°C. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed ab216773 and Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed ab216776 secondary antibodies at 1/10000 dilution for 1 h at room temperature before imaging.
Protocols
Datasheets and documents
-
SDS download
-
Datasheet download
References (4)
ab133251 has been referenced in 4 publications.
- Liu HF et al. Dipeptidyl peptidase-8 induces sorafenib resistance via binding with c-Rel to mediate NF-κB signaling in hepatocellular carcinoma. Cell Biol Int 46:213-221 (2022). PubMed: 34719075
- Zhu H et al. Knockdown of RSAD2 attenuates B cell hyperactivity in patients with primary Sjögren's syndrome (pSS) via suppressing NF-?b signaling pathway. Mol Cell Biochem 476:2029-2037 (2021). PubMed: 33512636
- Zhou Z et al. LncRNA XIST promotes inflammation by downregulating GRa expression in the adenoids of children with OSAHS. Exp Ther Med 21:500 (2021). PubMed: 33791009
- Zhang C et al. Activation of TNF-a/NF-?B axis enhances CRL4BDCAF11E3 ligase activity and regulates cell cycle progression in human osteosarcoma cells. Mol Oncol N/A:N/A (2018). WB . PubMed: 29377600